Toxoplasma gondii serin-protease inhibitor-1: a new adjuvant candidate for asthma therapy

ARIADNA SOTO; IGNACIO FENOY; VANESA SANCHEZ; MARIA DE LOS ANGELES ALDIRICO; MATÍAS PERRONE SIBILIA; MARIANO PICCHIO; NADIA ARCON; PATRICIO L. ACOSTA; VALENTINA MARTIN; ALEJANDRA GOLDMAN

Buenos Aires

Congreso; Congreso Sociedad Argentina de Inmunologia; 2015

Abstract: Immunotherapy is an alternative for asthma treatment.Using an experimental asthma model, we have shown that treatment with TgPI-1 plus allergen (PI+OVA) reduced lung eosinophilia and mucus production. Herein, we evaluated whether TgPI-1 treatment alone (PI) improve asthma symptoms. BALB/cmice were ip. sensitized with OVA/Alum and aerosol challenged. Later, they were intranasally treated with PI (PI) or PI+OVA (OPI). Controls included non-sensitized mice treated with PI alone (NPI), and sensitized mice treated with PBS (O) or OVA (OO). One week later, mice were re-challenged. PI and OPI groupsshowed reduced airway hyperresponsiveness (NPI:2,7±0,2; Oa:3,7±0,5; OOb:5,3±0,5; PIc:2,8±0,2; OPId:2,3±0,2; cmH2O.s/mL±ES,*, p